Market closedNon-fractional
Agenus/AGEN
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1YMAX
About Agenus
Agenus Inc is an American clinical-stage company with a pipeline of therapies designed to activate the body's immune system to fight cancer and infections, including immune-modulatory antibodies, adoptive cell therapies through its subsidiary MiNK Therapeutics Inc. and vaccine adjuvants through its subsidiary SaponiQx Inc. This robust product pipeline is supported by company's in-house capabilities, including current good manufacturing practice (cGMP) manufacturing and a clinical operations platform. The company's antibody candidates are botensilimab (a proprietary next-generation Fc-engineered CTLA-4 antibody, also known as AGEN1811) and balstilimab (a PD-1 antibody).
Ticker
AGEN
Sector
Healthcare
Trading on
NASDAQ
Industry
Biotechnology
Headquarters
Lexington, United States
Employees
389
Website
www.agenusbio.com
Agenus Metrics
BasicAdvanced
$305M
Market cap
-
P/E ratio
-$12.60
EPS
1.25
Beta
-
Dividend rate
Price and volume
Market cap
$305M
Beta
1.25
Financial strength
Current ratio
0.236
Quick ratio
0.208
Long term debt to equity
-33.883
Total debt to equity
-48.135
Interest coverage (TTM)
-1.25%
Management effectiveness
Return on assets (TTM)
-25.81%
Return on equity (TTM)
205.39%
Valuation
Price to revenue (TTM)
1.712
Price to book
-1.51
Price to tangible book (TTM)
-1.32
Price to free cash flow (TTM)
-1.304
Growth
Revenue change (TTM)
69.94%
Earnings per share change (TTM)
-22.29%
3-year revenue growth
23.95%
3-year earnings per share growth
-14.86%
What the Analysts think about Agenus
Analyst Ratings
Majority rating from 5 analysts.
Agenus Financial Performance
Income StatementBalance sheetCash Flow
Income Statement
Revenues and expenses
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$28M
-66.59%
Net income
-$62M
33.77%
Profit margin
-220.71%
300.34%
Agenus Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
-$4.00
-$3.20
-$2.60
-$3.04
-
Expected
-$3.97
-$3.84
-$1.05
-$3.22
-$1.50
Surprise
0.84%
-16.67%
147.62%
-5.47%
-
Agenus News
AllArticlesVideos
Significant Tumor Reductions in Neoadjuvant MSS Colon Cancer Patients Treated with Botensilimab/Balstilimab Presented at ESMO GI Conference
Business Wire·1 week ago
Agenus Announces Appointment of Dr. Jennifer Buell to Its Board of Directors
Business Wire·3 weeks ago
Nature Medicine Reports Agenus' Novel Immunotherapy Demonstrates Clinical Activity Against a Deadly Form of Colorectal Cancer on the Rise in Americans Under 50
Business Wire·3 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon
Market closedNon-fractional
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Agenus stock?
Agenus (AGEN) has a market cap of $305M as of July 06, 2024.
What is the P/E ratio for Agenus stock?
The price to earnings (P/E) ratio for Agenus (AGEN) stock is 0 as of July 06, 2024.
Does Agenus stock pay dividends?
No, Agenus (AGEN) stock does not pay dividends to its shareholders as of July 06, 2024.
When is the next Agenus dividend payment date?
Agenus (AGEN) stock does not pay dividends to its shareholders.
What is the beta indicator for Agenus?
Agenus (AGEN) has a beta rating of 1.25. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.
Buy or sell Agenus stock
Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.